Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.…
Aktis: Q3 Earnings Snapshot
Aktis Oncology (NASDAQ: AKTS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 79 employees.
The shares were at 16.15 USD on 20 November 2026. Its 52-week range is 13.96 USD to 34.19 USD: the price is 52.8% below the high and 15.7% above the low.
Its market capitalisation is 901.14M USD.
Aktis Oncology reports return on equity of 43.6% and revenue up 147.3% year over year.
It holds more cash than debt, a net cash position of 482.09M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 8 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 35.88 USD is 122.1% above the current price. The next earnings report is expected on 29 March 2027.